Understanding Idiopathic Pulmonary Fibrosis
Current treatments may help slow the progress of IPF in some people, but they do not stop or reverse it. Individuals living with IPF may benefit from new treatment options that go beyond slowing disease progression to reverse lung fibrosis and improve lung function.
Introducing ENV-101
Clinical Studies to Date
Endeavor BioMedicines recently evaluated ENV-101 in 21 patients with IPF. More information about this study is available at endeavorbiomedicines.com
The WHISTLE-PF Trial
Endeavor BioMedicines plans to initiate patient enrollment in a global trial designed to further evaluate the therapeutic potential of ENV-101 in individuals with IPF. The WHISTLE-PF clinical trial stands for Wound-remodeling Hedgehog-inhibitor ILD Study Testing Lung Function Endpoints. It is a Phase 2 trial evaluating the safety and efficacy of ENV-101.
Endeavor BioMedicines:
Disrupting Disease, Restoring Hope
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases.
Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF).
Copyright © Endeavor BioMedicines
Copyright © Endeavor BioMedicines